Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies.
model-informed precision dosing
non-adherence
pharmacokinetics
pharmacometrics
tamoxifen
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
24
12
2020
revised:
22
01
2021
accepted:
29
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
7
2
2021
Statut:
epublish
Résumé
Tamoxifen is widely used in breast cancer treatment and minimum steady-state concentrations of its active metabolite endoxifen (C
Identifiants
pubmed: 33546125
pii: ph14020115
doi: 10.3390/ph14020115
pmc: PMC7913149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Freie Universität Berlin
ID : Open Access Fund
Références
Clin Pharmacol Ther. 2011 May;89(5):718-25
pubmed: 21430657
J Clin Oncol. 2003 Feb 15;21(4):602-6
pubmed: 12586795
Clin Transl Sci. 2020 Mar;13(2):284-292
pubmed: 31573754
Breast Cancer Res Treat. 2012 May;133(1):367-73
pubmed: 22286315
Oncologist. 2016 Jul;21(7):795-803
pubmed: 27226358
Acta Oncol. 2018 Jul;57(7):935-940
pubmed: 29493327
Clin Pharmacol Ther. 2017 May;101(5):646-656
pubmed: 28182269
Breast Cancer Res Treat. 2004 May;85(1):89-97
pubmed: 15039600
Front Pharmacol. 2019 May 24;10:530
pubmed: 31178724
Clin Transl Sci. 2020 Jan;13(1):116-124
pubmed: 31647186
J Clin Oncol. 2010 May 10;28(14):2423-9
pubmed: 20385997
Clin Pharmacol Ther. 2011 Oct;90(4):605-11
pubmed: 21900890
Med Care. 2007 May;45(5):431-9
pubmed: 17446829
Breast Cancer Res Treat. 2012 Jul;134(2):459-78
pubmed: 22689091
Kaohsiung J Med Sci. 2015 Jun;31(6):328-34
pubmed: 26043413
Eur J Clin Pharmacol. 2021 Apr;77(4):441-464
pubmed: 33165648
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787
pubmed: 30255663
Clin Pharmacol Ther. 2011 May;89(5):708-17
pubmed: 21451508
Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536
pubmed: 31008668
Patient Educ Couns. 2005 Oct;59(1):97-102
pubmed: 16198223
Front Pharmacol. 2020 Mar 31;11:283
pubmed: 32296331
Br J Clin Pharmacol. 2021 Mar;87(3):1243-1252
pubmed: 32713032
Clin Cancer Res. 2016 Jul 1;22(13):3164-71
pubmed: 26847054
Pharmacogenomics J. 2015 Feb;15(1):84-94
pubmed: 25091503
J Clin Oncol. 2010 Sep 20;28(27):4120-8
pubmed: 20585090
J Clin Oncol. 1999 Sep;17(9):2659-69
pubmed: 10561339
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2:e50
pubmed: 23836189
Cancer Prev Res (Phila). 2011 Sep;4(9):1393-400
pubmed: 21862698
Breast Cancer Res Treat. 2012 Jan;131(1):137-45
pubmed: 21947681
J Clin Oncol. 2019 Feb 10;37(5):423-438
pubmed: 30452337
J Clin Oncol. 2011 Aug 20;29(24):3232-9
pubmed: 21768473
Breast Cancer Res Treat. 2006 Sep;99(2):215-20
pubmed: 16541307
Clin Pharmacol Ther. 2021 Jan;109(1):29-36
pubmed: 33068303
Breast Cancer Res Treat. 2015 Oct;153(3):583-90
pubmed: 26369533
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Clin Pharmacol Ther. 2008 Feb;83(2):234-42
pubmed: 17971818
Clin Pharmacokinet. 2018 Feb;57(2):229-242
pubmed: 28540639
Clin Pharmacol Ther. 2020 Sep;108(3):661-670
pubmed: 32578187
J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
pubmed: 15159443
J Clin Oncol. 2001 Jan 15;19(2):322-8
pubmed: 11208822
Breast J. 2006 Sep-Oct;12(5):446-50
pubmed: 16958964
Breast. 2014 Aug;23(4):400-6
pubmed: 24685597
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Clin Oncol. 2020 Aug 20;38(24):2762-2772
pubmed: 32568632
J Clin Oncol. 2009 Jul 20;27(21):3445-51
pubmed: 19451445
Clin Pharmacol Ther. 2018 May;103(5):770-777
pubmed: 29385237